Imunon (IMNN) Q2 2026 Earnings Call Transcript

Imunon (IMNN) held its Q2 2026 earnings call. Management reported Phase 2 OVATION II median overall survival of 45.1 months vs 30.4 months, and PARP maintenance survival of 65.6 vs 41.4 months. Q2 R&D was $1.5M, G&A $1.3M, net loss $2.8M. Cash was $6.9M after a $10M financing.

Original reporting
Published Aug 12, 2026, 4:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 4:17 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Imunon (IMNN) Q2 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$IMNNBullishMed
01

Why it matters

The most tradable elements are the newly disclosed efficacy datapoints (Phase 2 OS and biomarker outcomes), the operational update (Phase 3 enrollment rate and site activation), and the capital raise/runway details that affect dilution and funding risk.

02

Market read

Traders may reprice IMNN on the combination of stronger-than-control Phase 2 survival/biomarker signals and faster Phase 3 enrollment, balanced against funding needs and runway constraints.

03

What to watch

The call highlights a summer enrollment seasonal effect and only 35% of planned sites active, which could slow enrollment despite the reported rate; also, promissory note terms (5% and 8%) may increase future financing pressure.

Relevance 8/10Novelty 6/10Timing: pre-market today, Aug. 12, 2026 after Q2 call

Background

Imunon’s Q2 2026 earnings call focused on IMNN-001 clinical validation (OVATION II Phase 2 survival and MRD/ctDNA findings) and progress toward the pivotal OVATION III Phase 3 trial, alongside cash and financing updates.

Company-level read

Ticker impact

$IMNNBullishMedium confidence
Context

Imunon reported Q2 results and Phase 2 survival improvements for IMNN-001, plus Phase 3 enrollment and a $10M financing to fund OVATION III.

Expected impact

Near-term volatility likely, with upside bias on trial efficacy and enrollment metrics, tempered by dilution/financing overhang.

Evidence & confidence

The call discloses multiple efficacy datapoints (OS, maintenance survival, NED, ctDNA clearance) and operational progress (enrollment rate, site activation), alongside balance-sheet constraints (cash $6.9M, $10M raise, runway through year-end).

Market effects

Adds incremental validation for DNA-mediated immunotherapy in ovarian cancer, potentially supporting sentiment toward similar early-stage oncology platforms.

Limited, primarily US small-cap biotech investor focus.

Moderate, as ovarian cancer trial readouts can influence global biotech sentiment but are not a regulatory or approval event.

Counterpoint

Despite strong preliminary efficacy metrics, the MRD and ctDNA results are based on small preliminary cohorts, and Phase 3 still depends on continued enrollment and future financing.

Key entities

  • Imunon, Inc.

    Subject of the earnings call, reporting Phase 2/3 progress for IMNN-001 and Q2 financials plus a $10M financing.

  • IMNN-001

    DNA-based immunotherapy discussed as showing improved survival and biomarker outcomes in Phase 2 and advancing in Phase 3.

  • OVATION II

    Phase 2 study referenced for median overall survival and maintenance survival improvements.

  • OVATION III

    Pivotal Phase 3 trial referenced for enrollment rate, site activation, and expected completion timeline.

Related articles

$IMNNMedAI 8/10

Imunon (IMNN) Q3 2026 Earnings Call Transcript

Imunon (IMNN) reported Q3 2026 progress, highlighting Phase III IMNN-001 study for ovarian cancer. The company saw strong enrollment, independent validation, and a partnership with the National Cancer Institute. IMNN-001 aims to address a disease with low survival rates and limited treatment advances. The company expects 50% enrollment by Q1 2028 and completion by Q1 2029, with interim analysis in Q1 2030.

$IMNNLow

Imunon 3Q 2026: EPS ($0.64) — 10-Q Summary

Imunon (IMNN) reported a wider net loss of $3.81M in Q3 2026, though diluted EPS improved to ($0.64) from ($1.16) YoY. Operating expenses decreased 1%, with R&D costs down 6%. The OVATION 3 trial enrollment exceeded expectations, and the company advanced its NCI collaboration and MRD study. Imunon discontinued PLACCINE and IMNN-101 development in Q1 2026.

$IMNNMed

Imunon Reports Q3 2026 Net Loss of $3.8 Million and Advances IMNN-001

Imunon reported a Q3 2026 net loss of $3.8M, or $0.64 per share, compared to $3.4M, or $1.16 per share, a year earlier. Operating expenses were $3.4M. The company updated its Phase 3 ovarian cancer study and other programs, with enrollment expected to complete by Q1 2029. Imunon also transferred ThermoDox rights to VoxelDox, contingent on funding.

$IMNNHighAI 8/10

IMUNON Reports Third Quarter 2026 Financial Results and Provides Business Update

Imunon, Inc. (IMNN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 IMUNON Reports Third Quarter 2026 Financial Results and Provides Business Update IMNN-001 is the first frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer Enrollm

$IMNNHighAI 8/10

IMUNON presents translational data from ovarian cancer trial

IMUNON Inc. (IMNN) presented data from its Phase 2 OVATION 2 study of IMNN-001 in advanced ovarian cancer, showing improved survival and immune response. The trial compared IMNN-001 with chemotherapy against chemotherapy alone. The company is now conducting a Phase 3 trial, OVATION 3, to confirm these results. IMNN-001 is a DNA-based immunotherapy targeting IL-12 delivery to tumor tissue.

$IMNNMed

In an ovarian cancer trial, median survival was 14.7 months longer with added treatment

IMUNON, Inc. (Nasdaq: IMNN) announced new data from its Phase 2 OVATION 2 study, showing that IMNN-001 increased anti-tumoral T-cell activity in ovarian cancer patients. The treatment improved median overall survival by 14.7 months compared to standard care. The findings support the ongoing Phase 3 OVATION 3 trial. The data was presented at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting.